1. Keeling KL, Linder MW, Bukaveckas BL, Jortani SA, Valdes, RJr. A rigorous approach for investigation of unexpected phenytoin toxicity. Journal of Clin Ligand Immunoassay 2003;26(1):19-24
2. Bukaveckas BL, Kahn D, Valdes RJr., Linder MW. Stragety to determine basis for Warfarin resistance. Clin Chem 2003; 49 (suppl): A-120 (Abstract E-11).
3. Linder MW, Looney S, Adams JE, Johnson N, Antonino-Green D, Lacefield N, Bukaveckas BL, Valdes R.Jr. Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms. Journal of Thrombosis and Thrombolysis 2002;14(3):227-232.
4. Bukaveckas BL, Linder MW, Valdes JrR. Detection of CYP2C9*2 allele: comparison of denaturing HPLC (dHPLC) with restriction fragment length polymorphism (RFLP). Clin Chem 2002;48(11):2088
5. Keeling KL, Jortani SA, Linder MW. Valdes RJr. Prolonged elimination half-life of phenotoin in an elderly patient also on celecoxib. Clin Chem 2002;48(6):A52 Supp.
6. Linder MW, Johnson N, Valdes RJr. Design of genotyping methods based on pyro- phosphorolysis for pharmacogenetics. Clin Chem 2002;48(6):A49 Supp.
7. Linder, MW, Valdes R.Jr. Fundamentals of Pharmacogenetics. In: LM Shaw, ed. Contemporary Practices in Clinical Toxicology. Washington DC: AACC Press, 2001:437-453. [Book Chapter]
8. Linder MW, Valdes R, Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001;25:405-13.
9. Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 2000;295:179-85.
10. Linder MW, Valdes R, Jr. Pharmacogenetics in the practice of laboratory medicine. Mol Diagn 1999;4:365-79.
11. Cao Z, Linder MW, Jevans AW, Brown G, Valdes R, Jr. Comparison of tacrolimus concentrations measured by the IMx tacrolimus II vs the PRO-TRAC II FK506 ELISA assays. Clin Chem 1999;45:1868-70.
12. Linder MW, Valdes R, Jr. Fundamentals and applications of pharmacogenetics for the clinical laboratory. Ann Clin Lab Sci 1999;29:140-9.
13. Linder MW, Valdes R, Jr. Mechanism and elimination of aspirin-induced interference in Emit II d.a.u. assays. Clin Chem 1994;40:1512-6.
14. Wagener RE, Linder MW, Valdes R, Jr. Decreased signal in Emit assays of drugs of abuse in urine after ingestion of aspirin: potential for false-negative results. Clin Chem 1994;40:608-12.

Abstracts:

1. Bukaveckas BL, Khan D, Valdes R, Jr., Linder MW Pharmacodynamic Basis for Warfarin Resistance. Clin Chem 2003 (submitted)
2. Qiu LL, Valdes R, Jr., Johnson NA, Linder MW. Acetaminophen Poisoning Induces Hepatic Cytochrome P450 2E1 Clin Chem 2003.
3. Bukaveckas, BL, Linder MW, Valdes R, Jr. Detection of CYP2C9*2 allele: Comparison of denaturing HPLC (dHPLC) with restriction Fragment Length Polymorphism (RFLP). Clin Chem 2002;48:2088.
4. Keeling KL, Jortani, SA, Linder MW, Valdes R, Jr. Prolonged elimination half-life of phenytoin in an elderly patient also on celecoxib. Clin Chem 2002;48(S6): A52.
5. Linder MW, Johnson NA, Valdes R, Jr. Design of genotyping methods based on pyrophosphorolysis for pharmacogenetics. Clin Chem 2002;48(S6): A49
6. Linder MW, Antonino-Green D, Nota F, Johnson NA, Adams JE, Lacefield N, Valdes R, Jr. Predictive value of CYP2C9 genotyping for identification of subjects requiring low Warfarin maintenance dosages. Clin Chem. 2001;47:A75.
7. Linder MW, Liu LO, Antonino-Green DM, Valdes RJr. Suppression of CYP2E1 promoter activity by gamma-interferon and loss of response due to a naturally occurring G -35 T nucleotide sequence polymrphism. Clin Chem 2000;46:1881.
8. Linder MW, Qiu LL, Valdes R, Jr. Transcriptional activity of the CYP2E1 promoter is suppressed by gamma-interferon in HepG2 cells. Proceedings of the American Association for Cancer Research. 2001;42:899
9. Antonino-Green D, Linder MW, Fortwengler P, Looney S, Geoghegan TE, Valdes R, Jr. Cytochrome P4502E1 polymorphism and glutathione S-transferase genotypes are linked to vinyl chloride-induced angiosarcoma. Proceedings of the American Association for Cancer Research. 2000;41:437.
10. Linder MW, Nota F, Valdes R, Jr. Differences in CYP2C9 allele frequencies between American Caucasians, African Americans and native Africans. Clin Chem. 2000;46:A199.
11. Antonino-Green D, Linder MW, Qiu LL, Looney SW, Fortwengler PH, Valdes R, Jr. Ecogenetics of vinyl chloride-induced cancer is linked to a gamma-interferon dependent activation sequence in the cytochrome P4502E1 gene. Clin Chem 2000;46:A207.
12. Linder MW, Nota F, Valdes RM, Looney S, Valdes R, Jr. Criteria for establishing the use of pharmacogenetic (PG) analysis for optimizing warfarin therapy. Clin Chem 1999;45:6:A124.
13. Linder MW, Valdes RM, Looney S, Valdes R, Jr. An approach for design of pharmacogenetic (PG) screening -profiles and estimating impact on regional drug utilization. Clin Chem 1999;45;6:A125.
14. Linder MW, Valdes R, Jr. Pharmacogenetics (PG): Fundamentals and Applications to individualized drug therapy. J Clin Ligand Assay 1999;22:91.
15. Myers SR, Linder MW, Ross MP. Pharmacogenetics of maternal and fetal tobacco smoke exposure. The Toxicologist 1998;42(1-S):43.
16. Linder MW, Valdes R, Jr., Ross M, Myers SR. Fetal exposure to tobacco smoke carcinogens is increased by maternal GST M1 null genotype. Proceedings of the American Association for Cancer Research 1998;39:394.
17. Linder MW, Valdes RM, Valdes R, Jr. Genetic susceptibility to vinyl chloride-associated angiosarcoma. Therapeutic Drug Monitoring. 1997;19:595.
18. Linder MW, Valdes RM, Hendler FJ, Valdes R, Jr. CYP2E1 Genotype as a Biomarker of Cancer Risk. Proceedings of the American Association of Clinical Chemistry, Chicago, IL, 1996;42:S262.

Contact:

Maria R. Bradley

Administrative Secretary

MDR Bldg., Rm 216

511 S. Floyd St.

Louisville, KY 40292

Email: info@pgxlab.com

Web: http://www.pgxlab.com